Hyperthyroidism means the thyroid gland produces too much hormone, speeding up metabolism. About 1 in 100 Americans have it, most commonly from Graves' disease. Current treatment includes antithyroid pills like methimazole, radioactive iodine that destroys overactive thyroid tissue, or surgery to remove part or all of the gland.
What's actually going on in research
Trials are testing new antithyroid drugs with fewer side effects, monoclonal antibodies that target the immune attack in Graves' disease, and therapies to prevent the eye problems that often accompany Graves'. Researchers are also studying why some people develop hyperthyroidism after pregnancy or viral infections, and whether early treatment can prevent progression.
Graves' eye disease treatments
Teprotumumab, approved in 2020, reduces eye bulging and double vision in Graves' ophthalmopathy. Trials are testing longer-acting versions and drugs that might prevent eye disease from developing in the first place.
Targeted immune therapies
Several antibodies aim to block the immune attack that causes Graves' disease, potentially offering an alternative to destroying the thyroid. Early trials are testing whether they can restore normal thyroid function without permanent hypothyroidism.
What to know before you search
Eligibility typically depends on thyroid hormone levels, whether you have Graves' disease or another cause, presence of eye symptoms, and prior treatments like radioactive iodine or surgery.
What types of trials are currently open
- Treatment trials — Testing new antithyroid medications or different doses of existing drugs to control hormone levels with fewer side effects.
- Eye disease trials — Testing drugs for Graves' ophthalmopathy, including treatments to reduce bulging, double vision, and inflammation.
- Immune-targeting trials — Testing antibodies or other drugs that aim to stop the immune attack in Graves' disease rather than destroying thyroid tissue.
- Prevention trials — Studying whether early treatment after pregnancy or viral illness can prevent hyperthyroidism from developing or worsening.
- Quality of life studies — Following people with hyperthyroidism to understand how treatment affects symptoms like anxiety, heart palpitations, weight, and energy.
Recently added Hyperthyroidism trials
Track your heart rhythm with a wristband after thyroid surgery
The goal of this observational study is to determine whether nighttime heart rate and heart rhythm data collected by a smart wristband can identify under- or over-replacement with levothyroxine before the routine 1-month thyroid function tests in adults who have undergone total thyroidectomy. After total thyroidectomy, patients usually start levothyroxine replacement therapy, and the dose is adjusted about 1 month later based on thyroid function tests. This study aims to determine whether changes in nighttime heart rate and heart rhythm can provide an earlier indication that the levothyroxine dose is too low or too high. The main questions it aims to answer are: Can nighttime heart rate and heart rhythm measured by a smart wristband identify under- or over-replacement with levothyroxine before routine thyroid function testing? How well do smart wristband measurements agree with thyroid function test results? Participants will: Wear a smart wristband after total thyroidectomy. Continue taking levothyroxine as prescribed by their physician. Undergo routine thyroid function testing approximately 1 month after surgery as part of standard clinical care. Allow researchers to compare smart wristband measurements with thyroid function test results to evaluate whether wearable data can provide an earlier indication of inadequate or excessive levothyroxine replacement.
Complete MRI scans to help develop AI diagnosis tools for thyroid eye disease
The goal of this observational study is to prospectively validate the efficacy of an AI multimodal model constructed based on multi - sequence orbital MRI in the diagnosis, activity and severity assessment, and prognosis prediction of thyroid - associated ophthalmopathy (TAO) in real - world clinical scenarios. The main questions it aims to answer are: Can AI models accurately assess the presence, activity, and severity of Thyroid-Associated Orbitopathy (TAO)? Can AI models predict the prognosis of TAO? Researchers will compare the diagnostic accuracy of the AI model for TAO patients and healthy subjects to evaluate its diagnostic performance. Participants will undergo a standardized, study - specific multimodal orbital MRI scan (sequences include T1WI, T2WI, STIR, and research sequences such as Magic, IDEAL - IQ, DWI, ASL, CEST). And will systematically acquire ocular ultrasound images from TED patients (active and inactive stages), non-TED ophthalmic disease controls, and healthy volunteers. AI-driven deep learning techniques (convolutional neural networks) will be applied to achieve automatic segmentation of key structures (extraocular muscles, optic nerve, lacrimal gland, and retrobulbar soft tissue). High-throughput radiomic features encompassing morphological parameters and gray-level texture patterns will be extracted. Machine learning algorithms will then be employed to construct objective prediction models for TED screening and activity staging, with MRI findings and CAS scores serving as the reference standards for external validation.
Find Hyperthyroidism trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.